AU2020297592A1 - Combination therapy with Semaphorin-4D blockade (SEMA4D) and DC1 therapy - Google Patents

Combination therapy with Semaphorin-4D blockade (SEMA4D) and DC1 therapy Download PDF

Info

Publication number
AU2020297592A1
AU2020297592A1 AU2020297592A AU2020297592A AU2020297592A1 AU 2020297592 A1 AU2020297592 A1 AU 2020297592A1 AU 2020297592 A AU2020297592 A AU 2020297592A AU 2020297592 A AU2020297592 A AU 2020297592A AU 2020297592 A1 AU2020297592 A1 AU 2020297592A1
Authority
AU
Australia
Prior art keywords
cancer
oncodriver
sema4d
her2
pulsed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020297592A
Other languages
English (en)
Inventor
Brian Czerniecki
Elizabeth Evans
Krithika KODUMUDI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp
Vaccinex Inc
Original Assignee
H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp, Vaccinex Inc filed Critical H Lee Moffitt Cancer Center And Research Institute Inc A Florida Non Profit Corp
Publication of AU2020297592A1 publication Critical patent/AU2020297592A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2020297592A 2019-06-21 2020-06-19 Combination therapy with Semaphorin-4D blockade (SEMA4D) and DC1 therapy Pending AU2020297592A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962865027P 2019-06-21 2019-06-21
US62/865,027 2019-06-21
PCT/US2020/038719 WO2020257640A1 (en) 2019-06-21 2020-06-19 Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy

Publications (1)

Publication Number Publication Date
AU2020297592A1 true AU2020297592A1 (en) 2022-01-06

Family

ID=71575807

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020297592A Pending AU2020297592A1 (en) 2019-06-21 2020-06-19 Combination therapy with Semaphorin-4D blockade (SEMA4D) and DC1 therapy

Country Status (10)

Country Link
US (2) US11660330B2 (https=)
EP (1) EP3986446A1 (https=)
JP (1) JP7579284B2 (https=)
KR (1) KR20220044490A (https=)
CN (1) CN114364399A (https=)
AU (1) AU2020297592A1 (https=)
BR (1) BR112021025795A2 (https=)
IL (1) IL288779B2 (https=)
MX (1) MX2021015970A (https=)
WO (1) WO2020257640A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230390345A1 (en) * 2020-08-21 2023-12-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Combination therapy comprising her-2-dc1 vaccine, a probiotic, and semaphorin
WO2024159101A1 (en) * 2023-01-26 2024-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods for identifying disseminated cancer cells in breast cancer patients
WO2024159105A1 (en) * 2023-01-26 2024-08-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1601438A (https=) 1968-10-17 1970-08-24
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FR2686087A1 (fr) 1992-01-13 1993-07-16 Inst Nat Sante Rech Med Nouvel antigene lymphocytaire, anticorps correspondant et leurs applications.
US5652138A (en) 1992-09-30 1997-07-29 The Scripps Research Institute Human neutralizing monoclonal antibodies to human immunodeficiency virus
ATE183513T1 (de) 1993-06-03 1999-09-15 Therapeutic Antibodies Inc Herstellung von antikörperfragmenten
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6410690B1 (en) 1995-06-07 2002-06-25 Medarex, Inc. Therapeutic compounds comprised of anti-Fc receptor antibodies
FR2765243B1 (fr) 1997-06-30 1999-07-30 Usinor Acier inoxydable austenoferritique a tres bas nickel et presentant un fort allongement en traction
US7919594B2 (en) 2007-02-14 2011-04-05 Vaccinex, Inc. Human anti-CD100 antibodies
WO2010129917A2 (en) 2009-05-08 2010-11-11 Vaccinex, Inc. Anti-cd100 antibodies and methods for using the same
BR112015032690B1 (pt) 2013-06-25 2020-03-10 Vaccinex, Inc. Uso de moléculas inibidoras de semaforina-4d em combinação com uma terapia imunomoduladora para inibir o crescimento tumoral e metástase
CA2942721A1 (en) * 2014-03-14 2015-09-17 Czerniecki, Brian J. Methods for monitoring cd4+ t-helper type 1 response in cancer and immune restoration
CA2955445A1 (en) * 2014-07-17 2016-01-21 Brian J. Czerniecki Manufacturing of multi-dose injection ready dendritic cell vaccines and combination therapy for blocking her2 and her3
JP2018515421A (ja) * 2015-05-22 2018-06-14 ブライアン ジェイ ツェルニキＣＺＥＲＮＩＥＣＫＩ， Ｂｒｉａｎ， Ｊ． 複数用量注射準備済樹状細胞ワクチンの製造

Also Published As

Publication number Publication date
WO2020257640A1 (en) 2020-12-24
MX2021015970A (es) 2022-04-06
KR20220044490A (ko) 2022-04-08
EP3986446A1 (en) 2022-04-27
JP7579284B2 (ja) 2024-11-07
IL288779B2 (en) 2025-11-01
US20240050544A1 (en) 2024-02-15
IL288779A (en) 2022-02-01
CA3142777A1 (en) 2020-12-24
US11660330B2 (en) 2023-05-30
BR112021025795A2 (pt) 2022-02-01
JP2022537453A (ja) 2022-08-25
US20200397881A1 (en) 2020-12-24
CN114364399A (zh) 2022-04-15
IL288779B1 (en) 2025-07-01
US12201719B2 (en) 2025-01-21

Similar Documents

Publication Publication Date Title
US12201719B2 (en) Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
JP2023524530A (ja) 免疫原性が低い癌の癌細胞死滅を増強するための３剤併用療法
ES2894335T5 (es) Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
JP7473474B2 (ja) 抗体－薬物コンジュゲート投与による転移性脳腫瘍の治療
US20170106067A1 (en) Combinatorial immunotherapy for pancreatic cancer treatment
WO2023044432A2 (en) Targeting mutant kras with a mutation specific iga
KR20220133996A (ko) 암 및 암 전이를 치료하기 위한 병용 요법
CA3142777C (en) Combination therapy with semaphorin-4d blockade (sema4d) and dc1 therapy
US20220370496A1 (en) Her3 pulsed dc1 therapy
RU2801828C2 (ru) Комбинированная терапия блокированием семафорина 4d (sema4d) и терапией дк1
US20250376522A1 (en) Targeting Cells with a Combination of CXCR2 Inhibition and CD47 Blockade
WO2024036232A2 (en) Bispecific antibodies and uses thereof
US20240034788A1 (en) Abscopal therapy for cancer
JP2024502465A (ja) がんに対するｆｏｒ４６との併用療法
US20250230260A1 (en) Cdrs for glycosylated acat1
US20220169725A1 (en) Bio-responsive antibody complexes for enhanced immunotherapy
WO2024159105A1 (en) Methods of treating cancer comprising administration of intratumoral dcs in combination with systemic igg monoclonal antibody
US20260008844A1 (en) Use of anti-marco antibody with a checkpoint blockade antibody for the treatment of cancer
WO2024158763A2 (en) Lilrb2 binding molecules and methods of use
CN117355333A (zh) 包含抗tm4sf1抗体和免疫治疗药剂的组合及其使用方法
JP2025530130A (ja) 抗ｔｍｅｆｆ２×ｃｄ３二重特異性抗体でがんを治療する方法
CN115697374A (zh) 用于治疗胶质母细胞瘤的方法
EA053135B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
EA053283B1 (ru) Лечение метастатической опухоли головного мозга путем введения конъюгата антитело-лекарственное средство
CA2997130A1 (en) Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)